JY
LXEO icon

Jeff Yass’s Lexeo Therapeutics LXEO Stock Holding History

Jeff Yass’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-46,998
Closed -$254K – 14065
2026
Q1 		$270K Buy
46,998
+9,989
+27% +$70.8K ﹤0.01% 11112
2025
Q4 		$367K Buy
37,009
+8,078
+28% +$73.7K ﹤0.01% 9479
2025
Q3 		$192K Sell
28,931
-19,080
-40% -$92.3K ﹤0.01% 11039
2025
Q2 		$193K Sell
48,011
-2,136
-4% -$7.02K ﹤0.01% 11248
2025
Q1 		$174K Buy
50,147
+38,999
+350% +$173K ﹤0.01% 11086
2024
Q4 		$73.4K Buy
+11,148
New +$87.8K ﹤0.01% 11514
2024
Q2 		– Sell
-12,041
Closed -$189K – 12750
2024
Q1 		$189K Buy
+12,041
New +$188K ﹤0.01% 10657

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Jeff Yass's LXEO Position: Q2 2026 in Review

Jeff Yass sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 46,998 shares — an estimated $254K sold.

Jeff Yass first reported a position in LXEO in Q1 2024 and held it in 7 quarters. The position peaked at $367K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Jeff Yass reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 46,998 Lexeo Therapeutics shares in Q2 2026, an estimated $254K.
  • Jeff Yass first reported a position in Lexeo Therapeutics in Q1 2024 and held it in 7 quarters.
  • Jeff Yass's Lexeo Therapeutics position peaked at $367K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.